Pfizer could be left with up to 70 million surplus courses of Paxlovid by the end of 2022, data firm Airfinity warned, but the drug is still on track to be one of the year’s biggest.
Weak Demand For Covid Antivirals Dampens Roaring Sales
Pfizer could be left with up to 70 million surplus courses of Paxlovid by the end of 2022, data firm Airfinity warned, but the drug is still on track to be one of the year’s biggest.